RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets

Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy. On January 20, RBC Capital increased Ascendis Pharma A/S (NASDAQ:ASND)’s price target to $250 from $245 while maintaining an Outperform rating on the company. The firm’s improved projection comes after Ascendis Pharma A/S (NASDAQ:ASND) announced major goals for 2026, with the company estimating maintaining launch momentum for Yorvipath with no drop in patient intakes.

Ascendis Pharma A/S (NASDAQ:ASND) stated that the European potential could be more significant, with 150,000-200,000 patients vs 70,000-90,000 in the US, though the complex payer system demands patience. The company anticipates that the revenue split would eventually come to 60:40 U.S. to non-U.S.

In terms of financial estimates, Ascendis Pharma A/S (NASDAQ:ASND) reiterated its objective of €500 million in operating cash flow for this year and more than €5 billion in top-line revenue by 2030, in contrast to the consensus of around €3.5 billion, with Yorvipath predicted to earn €5-8 billion at its height.

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.